Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 156.79 percent decrease over earnings of $1.62 per share from the same period last year.
Artiva Biotherapeutics Q3 EPS $(0.92) Misses $(0.91) Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated